539 related articles for article (PubMed ID: 26864352)
41. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.
Citrome L
Expert Rev Neurother; 2017 Oct; 17(10):1029-1043. PubMed ID: 28832262
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study.
Xiao L; Zhao Q; Li AN; Sun J; Wu B; Wang L; Zhang H; Zhang R; Li K; Xu X; Liu T; Zhang W; Xie S; Xu X; Tan Y; Zhang K; Zhang H; Guan N; Xian M; Uki M; Wang G
Psychopharmacology (Berl); 2022 Jan; 239(1):243-251. PubMed ID: 34989824
[TBL] [Abstract][Full Text] [Related]
43. Aripiprazole Once-Monthly Versus Oral Aripiprazole for Schizophrenia in the Maintenance Phase: A Systematic Review and Network Meta-Analysis.
Kishi T; Sakuma K; Iwata N
Pharmacopsychiatry; 2022 Nov; 55(6):291-296. PubMed ID: 35790191
[TBL] [Abstract][Full Text] [Related]
44. Aripiprazole IM depot as an option for the treatment of bipolar disorder.
Kotzalidis GD; Rapinesi C; Chetoni C; De Filippis S
Expert Opin Pharmacother; 2021 Aug; 22(11):1407-1416. PubMed ID: 33847183
[No Abstract] [Full Text] [Related]
45. Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies.
Kane JM; Sanchez R; Baker RA; Eramo A; Peters-Strickland T; Perry PP; Johnson BR; Tsai LF; Carson WH; McQuade RD; Fleischhacker WW
Clin Schizophr Relat Psychoses; 2015; 9(2):79-87. PubMed ID: 25711509
[TBL] [Abstract][Full Text] [Related]
46. Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents.
Jann MW; Penzak SR
CNS Drugs; 2018 Mar; 32(3):241-257. PubMed ID: 29569082
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of patient support program and adherence to long-acting injectable aripiprazole for patients utilizing injection local care centers.
Greene M; Burudpakdee C; Seetasith A; Behling M; Krasa H
Curr Med Res Opin; 2019 Jan; 35(1):97-103. PubMed ID: 30322282
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study.
Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; Salzman PM; McQuade RD; Nyilas M; Carson WH
J Clin Psychiatry; 2017 Mar; 78(3):324-331. PubMed ID: 28146613
[TBL] [Abstract][Full Text] [Related]
49. Aripiprazole Lauroxil NanoCrystal
Ehret MJ; Davis E; Luttrell SE; Clark C
Clin Schizophr Relat Psychoses; 2018; 12(2):92-96. PubMed ID: 30040476
[TBL] [Abstract][Full Text] [Related]
50. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
Kane JM; Sanchez R; Perry PP; Jin N; Johnson BR; Forbes RA; McQuade RD; Carson WH; Fleischhacker WW
J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
[TBL] [Abstract][Full Text] [Related]
51. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
[TBL] [Abstract][Full Text] [Related]
52. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
[TBL] [Abstract][Full Text] [Related]
53. Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016-March 2019.
Peters L; Krogmann A; von Hardenberg L; Bödeker K; Nöhles VB; Correll CU
Curr Psychiatry Rep; 2019 Nov; 21(12):124. PubMed ID: 31745659
[TBL] [Abstract][Full Text] [Related]
54. Weight changes in people with early psychosis treated with oral or long-acting injectable aripiprazole.
Shymko G; Dobson L; Acacio MC; Grace T; Tadier S; Waters F
Schizophr Res; 2023 Jan; 251():74-81. PubMed ID: 36587541
[TBL] [Abstract][Full Text] [Related]
55. Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report.
Eum S; Schneiderhan ME; Brown JT; Lee AM; Bishop JR
BMC Psychiatry; 2017 Jul; 17(1):238. PubMed ID: 28673279
[TBL] [Abstract][Full Text] [Related]
56. Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS).
Novakovic V; Adel T; Peselow E; Lindenmayer JP
Clin Neuropharmacol; 2013; 36(2):59-62. PubMed ID: 23503549
[TBL] [Abstract][Full Text] [Related]
57. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW
J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
[TBL] [Abstract][Full Text] [Related]
58. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil.
Risinger R; Hard M; Weiden PJ
Psychopharmacol Bull; 2017 Aug; 47(3):26-34. PubMed ID: 28839337
[TBL] [Abstract][Full Text] [Related]
59. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia.
Turncliff R; Hard M; Du Y; Risinger R; Ehrich EW
Schizophr Res; 2014 Nov; 159(2-3):404-10. PubMed ID: 25266547
[TBL] [Abstract][Full Text] [Related]
60. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Li H; Rui Q; Ning X; Xu H; Gu N
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
